Panbela Therapeutics Inc (PBLA)
0.47
+0.06
(+14.63%)
USD |
OTCM |
May 02, 11:55
Panbela Therapeutics Enterprise Value: 4.606M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 4.606M |
| April 30, 2024 | 4.704M |
| April 29, 2024 | 4.729M |
| April 26, 2024 | 4.606M |
| April 25, 2024 | 4.752M |
| April 24, 2024 | 4.607M |
| April 23, 2024 | 4.655M |
| April 22, 2024 | 4.921M |
| April 19, 2024 | 4.655M |
| April 18, 2024 | 4.992M |
| April 17, 2024 | 5.121M |
| April 16, 2024 | 5.165M |
| April 15, 2024 | 5.238M |
| April 12, 2024 | 5.480M |
| April 11, 2024 | 5.432M |
| April 10, 2024 | 5.092M |
| April 09, 2024 | 5.286M |
| April 08, 2024 | 5.236M |
| April 05, 2024 | 5.265M |
| April 04, 2024 | 5.398M |
| April 03, 2024 | 5.403M |
| April 02, 2024 | 5.286M |
| April 01, 2024 | 5.286M |
| March 28, 2024 | 5.869M |
| March 27, 2024 | 5.892M |
| Date | Value |
|---|---|
| March 26, 2024 | 5.723M |
| March 25, 2024 | 5.723M |
| March 22, 2024 | 5.675M |
| March 21, 2024 | 4.952M |
| March 20, 2024 | 4.944M |
| March 19, 2024 | 4.809M |
| March 18, 2024 | 4.783M |
| March 15, 2024 | 4.705M |
| March 14, 2024 | 4.705M |
| March 13, 2024 | 4.879M |
| March 12, 2024 | 4.948M |
| March 11, 2024 | 5.227M |
| March 08, 2024 | 4.548M |
| March 07, 2024 | 5.018M |
| March 06, 2024 | 6.480M |
| March 05, 2024 | 6.898M |
| March 04, 2024 | 6.863M |
| March 01, 2024 | 7.037M |
| February 29, 2024 | 6.724M |
| February 28, 2024 | 6.759M |
| February 27, 2024 | 6.898M |
| February 26, 2024 | 6.620M |
| February 23, 2024 | 6.515M |
| February 22, 2024 | 6.480M |
| February 21, 2024 | 6.620M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.226M
Minimum
Jun 20 2023
70.64M
Maximum
Jul 14 2020
20.77M
Average
17.94M
Median
Feb 03 2022
Enterprise Value Benchmarks
| Processa Pharmaceuticals Inc | 1.634M |
| Fate Therapeutics Inc | 90.71M |
| Ardelyx Inc | 1.401B |
| Checkpoint Therapeutics Inc | 44.68M |
| Palisade Bio Inc | -6.287M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.474M |
| Total Expenses (Quarterly) | 7.044M |
| EPS Diluted (Quarterly) | -13.49 |
| Earnings Yield | -131.1K% |